This track will explore the latest advancements in immune checkpoint inhibitors, focusing on their mechanisms of action and clinical applications. Participants will discuss novel combinations and strategies to enhance therapeutic efficacy in various cancer types.

This session will delve into the development and optimization of CAR-T cell therapies, highlighting recent clinical trial outcomes and challenges. Discussions will also cover the potential for expanding CAR-T applications beyond hematological malignancies.

This track will examine the role of monoclonal antibodies in cancer immunotherapy, including their mechanisms of action and therapeutic applications. Participants will analyze recent clinical data and emerging trends in antibody engineering.

This session will focus on various immune modulation strategies aimed at enhancing anti-tumor responses. Topics will include the use of cytokines, immune adjuvants, and novel agents that can reshape the tumor microenvironment.

This track will address the current challenges in adoptive cell therapy, including T cell exhaustion and persistence. Innovations in cell engineering and the use of novel cellular products will also be discussed.

This session will explore the role of cytokines in modulating immune responses, with a focus on their therapeutic potential in cancer treatment. Participants will review recent findings on cytokine-based therapies and their clinical implications.